Drug Treatments for Polycystic Ovary Syndrome

LEE RADOSH, MD, The Reading Hospital and Medical Center, Reading, Pennsylvania

Polycystic ovary syndrome is a condition present in approximately 5 to 10 percent of women of childbearing age. Diagnosis can be difficult because the signs and symptoms can be subtle and varied. These may include hirsutism, infertility, menstrual irregularities, and biochemical abnormalities, most notably insulin resistance. Treatment should target specific manifestations and individualized patient goals. When choosing a treatment regimen, physicians must take into account comorbidities and the patient’s desire for pregnancy. Lifestyle modifications should be used in addition to medical treatments for optimal results. Few agents have been approved by the U.S. Food and Drug Administration specifically for use in polycystic ovary syndrome, and several agents are contraindicated in pregnancy. Insulin-sensitizing agents are indicated for most women with polycystic ovary syndrome because they have positive effects on insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Metformin has the most data supporting its effectiveness. Rosiglitazone and pioglitazone are also effective for ameliorating hirsutism and insulin resistance. Metformin and clomiphene, alone or in combination, are first-line agents for ovulation induction. Insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine can be used in patients with hirsutism. (Am Fam Physician. 2009;79(8):671-676. Copyright © 2009 American Academy of Family Physicians.)

Polycystic ovary syndrome (PCOS) is not a simple pathophysiologic process for which one treatment addresses all manifestations. It is a condition that occurs in approximately 5 to 10 percent of women of childbearing age. It can affect women in many different ways; therefore, physicians must individualize treatment goals and target treatment to specific manifestations. Comorbidities (e.g., cardiovascular risk factors, endocrinologic disease) and the patient’s desire for pregnancy must be considered when choosing a treatment regimen.

Diagnosis of PCOS may be difficult because the signs and symptoms can be subtle and varied. The most common manifestations include hirsutism, infertility, insulin resistance, and menstrual irregularities. Physicians can diagnose PCOS when other causes of the symptoms or laboratory abnormalities are excluded; when oligo-ovulation or anovulation, usually manifested as oligomenorrhea or amenorrhea, is present; and when there is clinically confirmed hyperandrogenism (e.g., hirsutism, acne). Although the ovaries may be polycystic, this is usually not necessary for diagnosis. There is debate over which criteria should be used (e.g., 1990 National Institutes of Health criteria, 2003 Rotterdam consensus workshop criteria). Guidelines suggest screening women with PCOS for other disorders, such as hyperlipidemia, and treating accordingly.

Limitations of Data on Drug Treatment for PCOS

There have been many studies on PCOS in the past several years; however, most are fairly small. Also, many studies examine medication effects on surrogate markers (e.g., androgen levels) rather than clinical outcomes (e.g., hirsutism). The study results are often conflicting, and in a recent systematic review, only 33 of 115 possible studies met basic inclusion criteria (e.g., randomized controlled trials), suggesting that many of the data in the literature may have methodologic flaws.

One of the biggest challenges in reviewing the evidence for PCOS treatment is that many manifestations of the condition may be components of other disease processes. For example, there may be a study of medications that are useful for hirsutism, but the patient population in the study did not explicitly have PCOS. Thus, recommendations specific for treating symptoms of PCOS...
may be lacking. When reviewing a study of the treatment of insulin resistance in a general population, it cannot be assumed that the outcomes would mirror those in women with PCOS.

Insulin-sensitizing agents are indicated for most women with PCOS because they have positive effects on insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Of all the drugs used to treat manifestations of PCOS, metformin (Glucophage) has the most data supporting its effectiveness. Table 1 details the most common medications used to treat manifestations of PCOS.6-27

**Medications for Manifestations of PCOS**

**HIRSUTISM**

Treatments for hirsutism in women with PCOS are similar to those in women without PCOS, such as patients with idiopathic hirsutism. There are many nonpharmacologic treatment options, including electrolysis, waxing, bleaching, plucking, depilatory creams (a form of hair removal that dissolves the hair), thermolysis (use of heat), and laser therapy. Several medications have been studied for the treatment of hirsutism in women with PCOS. First-line agents include spironolactone (Aldactone)22,23,28-30 and metformin,13,16,20,22,31-33 as well as eflornithine (Vaniqa) for facial hirsutism.9

Combination oral contraceptives, especially those with progestins of norgestimate, desogestrel, or drospirenone (because of their low androgenic effects), are among the most commonly used medications for hirsutism in women with PCOS.2 However, they are not approved by the U.S. Food and Drug Administration (FDA) for this use. One study found that women taking desogestrel/ethinyl estradiol (Apri) had lower hirsutism scores on a standardized scale (i.e., the Ferriman-Gallwey hirsutism score).34 Finasteride (Propecia) and flutamide (formerly Eulexin) are effective, but are FDA pregnancy categories X and D, respectively; the use of these agents for hirsutism is strictly off-label.2

Because of its antiandrogenic effects, spironolactone is effective, but not FDA-approved, for this indication.22,23 A Cochrane review suggested that spironolactone is superior to finasteride.24 Combining spironolactone with oral contraceptives may be synergistic, but caution should be used in women taking drospirenone because each agent can cause hyperkalemia.2 Spironolactone is FDA pregnancy category C.

Insulin-sensitizing agents, including metformin,31 acarbose (Precose),24 and rosiglitazone (Avandia),20 may be used to treat hirsutism in women with PCOS. Spironolactone22 and rosiglitazone32 have been shown to be more effective than metformin, based on Ferriman-Gallwey hirsutism scores. A Cochrane review suggested that metformin is as effective as oral contraceptives for treating hirsutism in women with PCOS,33 but in contrast, a recent systematic review suggested that metformin is not effective.1 Topical eflornithine cream is FDA-approved for management of unwanted facial hair, but there are no published data regarding its use.
<table>
<thead>
<tr>
<th>Manifestations treated</th>
<th>FDA pregnancy category</th>
<th>Main adverse effects</th>
<th>Typical dosage</th>
<th>Approximate monthly cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infertility</td>
<td>X</td>
<td>Multiple pregnancy/ovarian hyperstimulation, thromboembolism, visual disturbances</td>
<td>50 to 100 mg per day(^6)</td>
<td>$52 (generic) and $128 (brand) for 100 mg per day for 5 days</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>C</td>
<td>Mild skin irritation</td>
<td>13.9% cream applied to face twice per day(^9)</td>
<td>$46 (brand) for one 30-g tube</td>
</tr>
<tr>
<td>Hirsutism; infertility; insulin resistance; menstrual irregularities</td>
<td>B</td>
<td>GI upset, lactic acidosis, increase in homocysteine levels</td>
<td>1,500 to 2,250 mg per day(^10)-(^16)</td>
<td>$73 (generic) and $107 (brand) for 850 mg twice per day</td>
</tr>
<tr>
<td>Hirsutism; menstrual irregularities</td>
<td>X</td>
<td>Nausea, headache, spotting, thrombophlebitis, deep venous thrombosis</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>Hirsutism; infertility; insulin resistance</td>
<td>C</td>
<td>CHF, may cause weight gain</td>
<td>30 mg per day(^14),(^17),(^18)</td>
<td>$199 (brand)</td>
</tr>
<tr>
<td>Hirsutism; infertility; insulin resistance</td>
<td>C</td>
<td>CHF, hepatotoxicity, edema, increase in homocysteine levels</td>
<td>2 to 8 mg per day (beneficial effects are dose related)(^19)-(^21)</td>
<td>$113 (brand) for 4 mg per day</td>
</tr>
<tr>
<td>Hirsutism; menstrual irregularities</td>
<td>C</td>
<td>Hyperkalemia, nausea, breast tenderness</td>
<td>50 mg per day to 100 to 200 mg per day(^22),(^23)</td>
<td>$61 (generic) and $97 (brand) for 50 mg twice per day</td>
</tr>
<tr>
<td>Hirsutism; menstrual irregularities</td>
<td>B</td>
<td>GI upset</td>
<td>150 mg per day(^24) (for menses regulation)</td>
<td>$94 (brand)</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>X</td>
<td>Increased total cholesterol and low-density lipoprotein cholesterol; thromboembolism, stroke, MI</td>
<td>0.15 mg desogestrel plus 30 mcg ethinyl estradiol per day</td>
<td>$31 (brand)</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>X</td>
<td>Hypersensitivity reaction, decreased libido</td>
<td>5 mg per day(^25)</td>
<td>$148 (generic) and $100 to $343 (brand)</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>D</td>
<td>Thrombocytopenia, leukopenia, liver toxicity, hot flashes</td>
<td>250 mg once or twice per day(^25)</td>
<td>$140 (generic) for 250 mg per day</td>
</tr>
<tr>
<td>Infertility</td>
<td>C</td>
<td>Osteoporosis, thromboembolism, MI, hot flashes, arthralgias</td>
<td>2.5 mg per day(^6)</td>
<td>$340 (brand)</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>C</td>
<td>Tachycardia, hypertension, headache, dry mouth</td>
<td>10 mg per day(^26)</td>
<td>$116 (brand)</td>
</tr>
</tbody>
</table>

\(^\dagger\) — FDA-approved for female infertility caused by PCOS.

\(^\ddagger\) — Not studied specifically in women with PCOS; therefore, effectiveness is unknown.

\(^\S\) — Not FDA-approved for treatment of manifestations of PCOS.\(^27\)

\(\|\) — Based mostly on anecdotal evidence; cyproterone acetate plus ethinyl estradiol (drug not available in the United States) has been extensively studied.

\(^\dag\) — Studied in adolescents with PCOS.

Information from references 6 through 27.

specifically in women with PCOS. Sibutramine (Meridia), which is approved for obesity management, can also improve hirsutism.\(^26\)

**INFERTILITY**

Hormonal aberrations in women with PCOS (e.g., elevated androgen levels) can cause menstrual irregularities (e.g., oligomenorrhea, amenorrhea, anovulatory cycles) that can lead to dysfunctional uterine bleeding and infertility.\(^2\) First-line agents for ovulation induction and treatment of infertility in patients with PCOS include metformin\(^8\),\(^11\),\(^15\),\(^32\),\(^35\),\(^36\) and clomiphene (Clomid)\(^6\),\(^7\) alone or in combination, as well as rosiglitazone.\(^19\),\(^20\),\(^32\)

Clomiphene is an ovulation induction agent that has been used and studied in patients with and without PCOS.\(^6\)-\(^8\),\(^15\),\(^32\),\(^35\),\(^36\) Studies have found that letrazole (Femara)
regulates ovulation and improves pregnancy rates in women with PCOS \(^6,37,38\); however, this use is controversial because the drug is FDA pregnancy category D. It is embryotoxic and fetotoxic in animal studies, and there are no studies in pregnant women.

Insulin-sensitizing agents, including metformin, \(^9,32\) rosiglitazone, \(^9,20,32\) and pioglitazone (Actos), \(^17\) have been effective in improving fertility and ovulation in women with PCOS. There are contradictions in the literature regarding whether metformin, clomiphene, or a combination of the two agents is superior for improving pregnancy rates in women with PCOS. A 2003 Cochrane review suggested that metformin should be a first-line treatment for infertility in women with PCOS. \(^39\) A more recent study confirmed that six months of metformin therapy was more effective than six months of clomiphene therapy for improving fertility in anovulatory, nonobese women with PCOS. \(^9\) However, a large randomized trial of more than 600 women found that clomiphene is superior to metformin in achieving live birth in infertile women with PCOS, with no statistical benefit to the addition of metformin to clomiphene. \(^40\) Another study also showed no benefit from adding metformin to clomiphene. \(^35\) However, two meta-analyses suggested that the combination is better than clomiphene alone. \(^41,42\) A more recent study found that, although ovulation rates were better with metformin than with clomiphene, pregnancy rates were similar. \(^43\) Finally, two systematic reviews found conflicting results; one suggests metformin does not affect ovulation or pregnancy rates, \(^1\) and the other suggests it does. \(^44\)

**INSULIN RESISTANCE**

The prevalence of insulin resistance in women with PCOS, as measured by impaired glucose tolerance, is substantially higher than expected compared with age- and weight-matched populations of women without PCOS. \(^45\) Although insulin resistance alone is a laboratory (not clinical) aberration, it can lead to diabetes, and it may be associated with the metabolic syndrome, thus leading to increased cardiovascular risk. \(^2\) As with diabetes, optimal treatment of PCOS requires lifestyle modifications (e.g., diet, exercise) in addition to appropriate medications.

Metformin improves insulin resistance, as diagnosed by elevated fasting glucose or fasting glucose/insulin ratios, in patients with PCOS \(^10,16,46,47\) and is probably the best agent to use. Women with PCOS who are not obese may benefit more from metformin than women who are obese. \(^13,48\) Metformin is FDA pregnancy category B.

Other insulin-sensitizing agents are also effective for improving insulin resistance in women with PCOS, including rosiglitazone \(^9,21\) and pioglitazone. \(^14,17,18\) However, these agents may cause or worsen congestive heart
failure, according to recent black box warnings,27 or cause unwanted weight gain.

If a woman’s weight is excessive, the physician should be aggressive in championing a weight-loss program. Medications effective for weight loss (in addition to lifestyle modifications) that have been specifically studied in women with PCOS include metformin, acarbose, sibutramine, and orlistat (Xenical). Metformin is probably the first-line medication for obesity or weight reduction in patients with PCOS. Metformin results in a decrease in body mass index (BMI) of 1 to 2 kg per m$^2$ or weight loss up to 6 lb, 10 oz to 8 lb, 13 oz (3 to 4 kg)$^{10,46,48}$; acarbose results in an approximate 3 kg per m$^2$ decrease in BMI$^{24}$; sibutramine results in a decrease in BMI of 5.8 kg per m$^2$ and weight loss of 31 lb, 11 oz (14.4 kg)$^{25}$; and orlistat results in weight loss of approximately 11 lb (5 kg).$^{20}$ However, a recent systematic review suggested that metformin is not effective for lowering BMI in patients with PCOS.$^1$

**MENSTRUAL IRREGULARITIES**

Anecdotally, oral contraceptive agents are among the most common agents used to treat menstrual irregularities in women with PCOS. However, there are few studies examining their effect on menstrual cycles in women with PCOS. Ciproterone acetate plus ethinyl estradiol has been extensively studied, but it is not available in the United States. Studies suggest that the following agents may improve menstrual irregularities (e.g., oligomenorrhea): spironolactone (in an open-label study),$^{22}$ acarbose,$^{24}$ rosiglitazone,$^{32}$ and metformin.$^{10,11,32,47,51}$ Metformin is probably the best choice because it may improve insulin resistance in addition to improving menstrual irregularities.

This is one in a series of “Clinical Pharmacology” articles coordinated by Allen F. Shaugnessy, PharmD, Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Mass.

The author thanks Mary Lisney, MA, and Rose Reerer for assistance in the preparation of the manuscript, and Shahab S. Minassian, MD, a founding member and first chair of the Androgen Excess (PCOS) Special Interest Group of the American Society for Reproductive Medicine, for his review of the manuscript.

The Author

LEE RADOSH, MD, FAAFP, is associate director of the Family Medicine Residency Program at The Reading (Pa.) Hospital and Medical Center; a clinical assistant professor in the Department of Family, Community and Preventive Medicine at Drexel University College of Medicine, Philadelphia, Pa.; and a clinical assistant professor in the Department of Family and Community Medicine, Penn State College of Medicine, Hershey, Pa. He received his medical degree from Temple University School of Medicine, Philadelphia, Pa., and completed a family medicine residency at Lancaster (Pa.) General Hospital and a faculty development fellowship at Michigan State University, East Lansing.

Address correspondence to Lee Radosh, MD, The Reading Hospital and Medical Center, Suite 2120 DOB, 301 S. 7th Ave., Reading, PA 19611 (e-mail: RadoshL@readinghospital.org). Reprints are not available from the author.

Author disclosure: Nothing to disclose.

**REFERENCES**


14. Harborel L, Fleming R, Lyll H, Sattar N, Norman J. Metformin or anti-
Polycystic Ovary Syndrome

androgen in the treatment of hirsutism in polycystic ovary syndrome. 
J Clin Endocrinol Metab. 2003;88(9):4116-4123.

17. Bretenthaler N, De Geyer C, Huber PR, Keller U. Effect of the insulin
sensitizer pioglitazone on insulin resistance, hyperandrogenism, and
ovulatory dysfunction in women with polycystic ovary syndrome. J Clin
Endocrinol Metab. 2004;89(8):3835-3840.

glucose metabolism and luteinizing hormone secretion in women with

of rosiglitazone treatment for 12 weeks in insulin-resistant women with
polycystic ovary syndrome. Hum Reprod. 2006;21(1):109-120.

20. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and
metabolic effects of rosiglitazone in non-obese women with polycystic

21. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and
ethinyl estradiol/cyproterone acetate as single and combined treatment
of overweight women with polycystic ovary syndrome and insulin resis-

22. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of
spiranolactone with metformin in the management of polycystic ovary
syndrome: an open-labeled study [published correction appears in
J Clin Endocrinol Metab. 2004;89(9):4655]. J Clin Endocrinol Metab.
2004;89(6):2756-2762.

mide, and finasteride in the treatment of hirsutism: a randomized,
double blind, placebo-controlled trial. J Clin Endocrinol Metab.

24. Penha IA, Canella PR, Reis RM, Silva de Sá MF, Ferriani RA. Acar-
bose in obese patients with polycystic ovarian syndrome: a double-
blind, randomized, placebo-controlled study. Hum Reprod. 2005;
20(9):2396-2401.

25. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of
finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrino-

26. Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a
positive effect on clinical and metabolic parameters in obese patients

27. Micromedex Healthcare Series [Internet database]. Greenwood Village,
Colo.: Thomson Healthcare; updated periodically.

or in combination with steroids for hirsutism and/or acne. Cochrane

29. Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy
of flutamide and spironolactone plus Diane 35 in the treatment of idio-
pathic hirsutism: a randomized controlled study. Fertil Steril. 2005;
84(6):1693-1697.

30. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single
agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf).

31. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic

and metformin on menstrual cyclicity and hirsutism in polycystic ovary

drugs versus the combined oral contraceptive pill for hirsutism, acne
and risk of diabetes, cardiovascular disease, and endometrial cancer in

34. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contracep-
tive treatment of adolescent girls with polycystic ovary syndrome. Lipid

35. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomi-
fene citrate plus metformin and clomifene citrate plus placebo on induction
of ovulation in women with newly diagnosed polycystic ovary syndrome:

36. Kasihy S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary
therapy for patients with polycystic ovarian syndrome. Hum Reprod.

37. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction
of ovulation in patients with an inadequate response to clomiphene

38. Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-
letrozole in comparison with metformin-clomiphene citrate in clomi-
phene-resistant infertile women with polycystic ovarian disease. Hum

39. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin,
troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic

40. Legro RS, Barnhart HK, Schlaff WD, et al. Clomiphene, metformin, or
both for infertility in the polycystic ovary syndrome. N Engl J Med.

41. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome:

42. Siebert TI, Kruger TF, Steyn DW, Nosarka S. Is the addition of metfor-
min efficacious in the treatment of clomiphene citrate-resistant patients
with polycystic ovary syndrome? A structured literature review. Fertil

43. Neveu N, Granger L, St-Michel P, Lavoie HB. Comparison of clomiphene
citrate, metformin, or the combination of both for first-line ovulation
induction and achievement of pregnancy in 154 women with polycystic

44. Creaga AA, Bradley HM, McCormick C, Wiltcop CT. Use of metfor-

45. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Preva-
lence of impaired glucose tolerance and diabetes in women with poly-

46. Allen HF, Mazzoni C, Heptulla RA, et al. Randomized controlled trial
evaluating response to metformin versus standard therapy in the treat-
ment of adolescents with polycystic ovary syndrome. J Pediatr Endocri-
nol Metab. 2005;18(8):761-768.

47. Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metfor-
min in women with polycystic ovary syndrome: a prospective random-
ized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab.
2006;91(3):946-952.

GR, Baracat EC. Nonobese women with polycystic ovary syndrome
respond better than obese women to treatment with metformin. Fertil

49. Harborne LR, Sattar N, Norman JE, Fleming RJ. Metformin and weight

50. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is
as beneficial as metformin in the treatment of polycystic ovarian syn-

51. Bridger T, MacDonald S, Baitzer F, Rodd C. Randomized placebo-con-
trolled trial of metformin for adolescents with polycystic ovary syn-

676 American Family Physician www.aafp.org/afp Volume 79, Number 8 • April 15, 2009